FDMT

4D Molecular Therapeutics, Inc.

FDMT

4D Molecular Therapeutics, Inc.

dashboardOverview

paymentsDividend

newspaperNews

4D Molecular Therapeutics, Inc.

FDMT

NASDAQ

$ -

Review earnings summary, surprise history, and upcoming forecasts.

account_balance_walletEarnings Summary

Updated: 05/07/2026FY2026 Q1

Revenue (TTM)

3M USD

YoY +21664.3%

Net Income (TTM)

-69M USD

YoY Expanded Deficit

Equity Ratio

88.1%

YoY -3.0pt

BPS

6.64$

YoY -21.2%

Revenue

$3M

FY2024 Q2$33,000

$33,000

FY2024 Q3$36,000

$36,000

FY2024 Q4$37,000

$37,000

FY2025 Q1$14,000

$14,000

FY2025 Q2$29,000

$29,000

FY2025 Q3$119,000

$119,000

FY2025 Q4$85.2M

$85.2M

FY2026 Q1$3M

$3M

Actual

YoY+$3M (+21664.3%)

Net Income

$-68.8M

FY2024 Q2$-67.4M

$-67.4M

FY2024 Q3$-111.2M

$-111.2M

Surprise History

Actual RevenueAnalyst Estimate

FY2021MISS

Actual:$18M

Est:$18.8M

FY2021MISS

$18M

Earnings Release History

View as charts

4D Molecular Therapeutics, Inc.

account_balance_walletEarnings Summary

Revenue

Net Income

Surprise History

Earnings Release History

Analyst Estimates